The average P/S ratio for RXRX's competitors is 1218.28, providing a benchmark for relative valuation. Recursion Pharmaceuticals Inc Corp (RXRX) exhibits a P/S ratio of 28.30, which is -97.68% above the industry average. Given its robust revenue growth of 6.89%, this premium appears unsustainable.